- Home
- ECCC vs SNN Comparison
ECCC vs SNN Comparison
Compare ECCC & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECCC | SNN |
|---|---|---|
| Founded | N/A | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 14.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ECCC | SNN |
|---|---|---|
| Price | $23.85 | $32.96 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $36.25 |
| AVG Volume (30 Days) | 6.4K | ★ 841.3K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.28% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $7.19 |
| Revenue Next Year | N/A | $5.36 |
| P/E Ratio | ★ N/A | $64.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.87 | $23.91 |
| 52 Week High | $25.00 | $38.79 |
Technical Indicators
Market Signals| Indicator | ECCC | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 39.13 | 37.60 |
| Support Level | $23.93 | $32.08 |
| Resistance Level | $23.95 | $33.89 |
| Average True Range (ATR) | 0.24 | 0.71 |
| MACD | -0.07 | -0.44 |
| Stochastic Oscillator | 39.28 | 11.80 |
Price Performance
Historical ComparisonAbout ECCC Eagle Point Credit Company Inc. 6.50% Series C Term Preferred Stock due 2031
Eagle Point Credit Co Inc. is an externally managed, non-diversified closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective of capital appreciation. The Company seeks to achieve its investment objectives by investing in equity and junior debt tranches of collateralized loan obligations ("CLOs") collateralized by a portfolio consisting of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors. The Company intends to operate so as to qualify to be taxed as a regulated investment company.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.